Sees FY19 revenue $217.0M-$221.0M, consensus $218.13M.
Thursday, May 9, 2019
Mersana Therapeutics reports Q1 EPS 72c, consensus (2c)
Reports Q1 revenue $41.0M, consensus $20.6M.
Flexion upgraded to Buy from Hold at Benchmark
Benchmark analyst Bruce Jackson upgraded Flexion Therapeutics to Buy from Hold with a $19 price target
Wednesday, May 8, 2019
Phibro Animal Health upgraded to Buy from Hold at Gabelli
Gabelli analyst Kevin Kedra upgraded Phibro Animal Health to Buy from Hold.
Protagonist Therapeutics upgraded to Buy from Hold at Stifel
Stifel analyst Adam Walsh upgraded Protagonist Therapeutics to Buy from Hold and raised his price target for the shares to $17 from $11.
Subscribe to:
Posts (Atom)